Vertical integration of healthcare cuts readmission rates

Improving the communication and coordination of primary care and hospitals is commonly known as vertical integration, and was found to be effective in reducing hospital readmission. In a study, published in in Medical Care, researchers analyzed the vertical integration of healthcare in Portugal which led to reduced hospital readmissions for a variety of conditions.

From 1999 to 2001, Portuguese Ministry of Health combined primary care and public hospitals to create Local Health Units (LHUs) to improve efficiency and effectiveness. The vertical integration of the healthcare system, while also used in other countries, is scarce in its research into the benefits it provides. Led by Sílvia Lopes, PhD, and colleagues of NOVA National School of Public Health, Universidade NOVA de Lisboa, the study aims at providing evidence on how the vertical integration affects healthcare outcomes and patient care.

The study evaluated an unplanned 30-day readmissions before and after the implementation of vertical integration from 2004 to 2013 in six hospitals. Results showed that readmission rates at vertically integrated hospitals were measured at 4.8 percent compared to 5.4 percent from the control group. Readmission rate improvement was shown to have a 30 percent reduction in patients previously admitted with diabetic complications, urinary tract infections and pneumonia.

"Given that reducing readmissions was not an explicit goal of the policy, the findings suggest the potential of vertical integration and the resulting increased care coordination to reduce readmissions," said Lopes. "These findings suggest that vertical integration can have a positive impact, but there are still challenges to be addressed regarding the success of vertical integration in reducing 30-day hospital readmissions.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.